Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study

Gut

Volumn 45, Issue 4, 1999, Pages 489-494

  Peters, F T M ^a   Ganesh, S ^b   Kuipers, E J ^c   Sluiter, W J ^a   Klinkenberg Knol, E C ^c   Lamers, C B H W ^b   Kleibeuker, J H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acid reflux; Barrett's oesophagus; Omeprazole; Regression

Indexed keywords

OMEPRAZOLE; RANITIDINE;

ADULT; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESOPHAGOSCOPY; ESOPHAGUS CANCER; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0032834176     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.45.4.489     Document Type: Article

References (30)

1. Paull A, Trier JS, Dalton MD, et al. The histologic spectrum of Barrett's esophagus. N Engl J Med 1976;295:476-80.
2. Spechler SJ, Robbins AH, Bloomfield Rubins H, et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology 1984;87:927-33.
3. Iftikhar SY, James PD, Steele RJC, et al. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 1992;33:1155-8.
4. GOSPE. Barrett's esophagus and risk of adenocarcinoma [abstract]. Gastroenterology 1992;102:A75.
5. Chow W, Finkle WD, McLaughlin JK, et al. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995;274:474-7.
6. Ritenbaugh C, Sampliner R, Aickin M, et al. Risk factors for Barrett's oesophagus: a life history approach to behavioural assessment in the distant past. Eur J Cancer Prev 1995;4:459-68.
7. Menke Pluymers MBE, Hop WCJ, Dees J, et al. Risk factors for the development of an adenocarcinoma in columnarlined (Barrett) esophagus. Cancer 1993;72:1155-8.
8. Devière J, Buset M, Dumonceau J, et al. Regression of Barrett's epithelium with omeprazole. N Engl J Med 1989;320:1497-8.
9. Ottenjann B, Heidt H. Regression der Zylinderepithel-Metaplasie bei Barrett-Oesophagus. Disch Med Wochenschr 1990;115:916-17.
10. Gore S, Healey CJ, Sutton R, et al. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993;7:623-8.
11. Neumann CS, Iqbal TH, Cooper BT. Long term continuous omeprazole treatment of patients with Barrett's oesophagus. Aliment Pharmacol Ther 1995;9:451-4.
12. Malesci A, Savarino V, Zentilin P, et al. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996;44:700-5.
13. Shaffer RT, Francis J, Carrougher JG, et al. Effect of omeprazole on Barrett's epithelium after 3 years of therapy [abstract]. Gastroenterology 1996;110:A255.
14. Caldwell MTP, Byrne PJ, Walsh TN, et al. A randomised trial on the effect of acid suppression on regression of Barrett's oesophagus [abstract]. Gastroenterology 1996;110:A74.
15. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-close proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997;92:582-5.
16. Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol 1994;89:1844-8.
17. Sharma P, Morales TG, Bhattacharyya A, et al. Squamous islands in Barrett's esophagus: what lies underneath? Am J Gastroenterol 1998;93:332-5.
18. Weinstein WM, Lieberman DA, Lewin KJ, et al. Omeprazole-induced regression of Barrett's esophagus: a 2 year, randomized, controlled double blind trial. Gastroenterology 1996;110:A294.
19. Kim R, Baggott BB, Rose S, et al. Quantitative endoscopy: precise computerized measurement of metaplastic epithelial surface area in Barrett's esophagus. Gastroenterology 1995;108:360-6.
20. Le Rhun M, Boyer J, Goldfain D, et al. Long-term omeprazole effects on Barrett's mucosa [abstract]. Gastroenterology 1996;110:A174.
21. Johnson DA, Winters C, Spurling TJ, et al. Esophageal acid sensitivity in Barrett's esophagus. J Clin Gastroenterol 1987;9:23-7.
22. Orr WC, Lackey C, Robinson MG, et al. Esophageal acid clearance during sleep in patients with Barrett's esophagus. Dig Dis Sci 1988;33:654-9.
23. Murphy PP, Johnston BT, Collins JSA. Mucosal sensitivity and salivary response to infused acid in patients with columnar-lined oesophagus. Eur J Gastroenterol Hepatol 1994;6:901-5.
24. Bremner RM, DeMeester TR, Bremner CG, et al. Further evidence of altered sensitivity to reflux in patients with Barrett's esophagus. Gastroenterology 1996;110:A640.
25. Katzka DA, Castell DO. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1994;89:989-91.
26. Berenson MM, Johnson TD, Markowitz NR, et al. Restoration of squamous mucosa after ablation of Barrett's esophageal epithelium. Gastroenterology 1993;104:1686-91.
27. Sampliner RE, Fennerry MB, Garewal HS. Controlled trial of reversal of Barrett's esophagus with acid suppression and multi-polar electrocoagulation (MPEC) [abstract]. Gastroenterology 1995;108:A208.
28. Barr H, Shepherd NA, Dix A, et al. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 1996;348:584-5.
29. Overholt BF, Panjehpour M. Photodynamic therapy for Barrett's esophagus: clinical update. Am J Gastroenterol 1996;91:1719-23.
30. Barham CP, Jones RL, Biddlestone LR, et al. Photothermal laser ablation of Barrett's oesophagus: endoscopic and histological evidence of squamous re-epithelialisation. Gut 1997;41:281-4.